---
schema_version: "secwatch.filing_event.v1"
accession: "0000921895-21-001834"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2021-07-09T23:59:59+00:00"
generated_at: "2026-06-30T06:22:40.296430+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# CFO Michael Donaldson departs; Duggan interim CFO, Maranian accounting officer

## Summary
- Michael Donaldson departed as CFO effective July 2, 2021.
- Robert W. Duggan (CEO & Executive Chairman) appointed interim principal financial officer.
- Jeffrey R. Maranian (Corporate Controller since Nov 2020) appointed principal accounting officer.

## SEC filing metadata
- accession: 0000921895-21-001834
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2021-07-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/form8k12566003_07082021.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000921895-21-001834
- JSON: https://secwatch.observer/filing/0000921895-21-001834.json
- Plain text: https://secwatch.observer/filing/0000921895-21-001834.txt

## Key facts
- Executive change
  Jeffrey R. Maranian was appointed as principal accounting officer at Summit Therapeutics Inc..
  - Action: appointed
  - Role: principal accounting officer
  source text: the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm
- Executive change
  Michael Donaldson departed as Chief Financial Officer at Summit Therapeutics Inc..
  - Action: departed
  - Role: Chief Financial Officer
  source text: Effective on July 2, 2021 in connection with the departure of Michael Donaldson as Chief Financial Officer of Summit Therapeutics Inc. (the “Company”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm
- Executive change
  Robert W. Duggan was appointed as interim principal financial officer at Summit Therapeutics Inc..
  - Action: appointed
  - Role: interim principal financial officer
  source text: the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.